Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum

Benjamin K. Dickerman, Brendan Elsworth, Simon A Cobbold, Catherine Q Nie, Malcolm J McConville, Brendan S. Crabb, Paul R. Gilson

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Plasmodium parasites are responsible for the devastating disease malaria that affects hundreds of millions of people each year. Blood stage parasites establish new permeability pathways (NPPs) in infected red blood cell membranes to facilitate the uptake of nutrients and removal of parasite waste products. Pharmacological inhibition of the NPPs is expected to lead to nutrient starvation and accumulation of toxic metabolites resulting in parasite death. Here, we have screened a curated library of antimalarial compounds, the MMV Malaria Box, identifying two compounds that inhibit NPP function. Unexpectedly, metabolic profiling suggested that both compounds also inhibit dihydroorotate dehydrogense (DHODH), which is required for pyrimidine synthesis and is a validated drug target in its own right. Expression of yeast DHODH, which bypasses the need for the parasite DHODH, increased parasite resistance to these compounds. These studies identify two potential candidates for therapeutic development that simultaneously target two essential pathways in Plasmodium, NPP and DHODH.

Original languageEnglish
Article number37502
Number of pages15
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 22 Nov 2016

Cite this

Dickerman, Benjamin K. ; Elsworth, Brendan ; Cobbold, Simon A ; Nie, Catherine Q ; McConville, Malcolm J ; Crabb, Brendan S. ; Gilson, Paul R. / Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum. In: Scientific Reports. 2016 ; Vol. 6.
@article{82ba3c52bc244109bd53127baa93c7e6,
title = "Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum",
abstract = "Plasmodium parasites are responsible for the devastating disease malaria that affects hundreds of millions of people each year. Blood stage parasites establish new permeability pathways (NPPs) in infected red blood cell membranes to facilitate the uptake of nutrients and removal of parasite waste products. Pharmacological inhibition of the NPPs is expected to lead to nutrient starvation and accumulation of toxic metabolites resulting in parasite death. Here, we have screened a curated library of antimalarial compounds, the MMV Malaria Box, identifying two compounds that inhibit NPP function. Unexpectedly, metabolic profiling suggested that both compounds also inhibit dihydroorotate dehydrogense (DHODH), which is required for pyrimidine synthesis and is a validated drug target in its own right. Expression of yeast DHODH, which bypasses the need for the parasite DHODH, increased parasite resistance to these compounds. These studies identify two potential candidates for therapeutic development that simultaneously target two essential pathways in Plasmodium, NPP and DHODH.",
author = "Dickerman, {Benjamin K.} and Brendan Elsworth and Cobbold, {Simon A} and Nie, {Catherine Q} and McConville, {Malcolm J} and Crabb, {Brendan S.} and Gilson, {Paul R.}",
year = "2016",
month = "11",
day = "22",
doi = "10.1038/srep37502",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum. / Dickerman, Benjamin K.; Elsworth, Brendan; Cobbold, Simon A; Nie, Catherine Q; McConville, Malcolm J; Crabb, Brendan S.; Gilson, Paul R.

In: Scientific Reports, Vol. 6, 37502, 22.11.2016.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum

AU - Dickerman, Benjamin K.

AU - Elsworth, Brendan

AU - Cobbold, Simon A

AU - Nie, Catherine Q

AU - McConville, Malcolm J

AU - Crabb, Brendan S.

AU - Gilson, Paul R.

PY - 2016/11/22

Y1 - 2016/11/22

N2 - Plasmodium parasites are responsible for the devastating disease malaria that affects hundreds of millions of people each year. Blood stage parasites establish new permeability pathways (NPPs) in infected red blood cell membranes to facilitate the uptake of nutrients and removal of parasite waste products. Pharmacological inhibition of the NPPs is expected to lead to nutrient starvation and accumulation of toxic metabolites resulting in parasite death. Here, we have screened a curated library of antimalarial compounds, the MMV Malaria Box, identifying two compounds that inhibit NPP function. Unexpectedly, metabolic profiling suggested that both compounds also inhibit dihydroorotate dehydrogense (DHODH), which is required for pyrimidine synthesis and is a validated drug target in its own right. Expression of yeast DHODH, which bypasses the need for the parasite DHODH, increased parasite resistance to these compounds. These studies identify two potential candidates for therapeutic development that simultaneously target two essential pathways in Plasmodium, NPP and DHODH.

AB - Plasmodium parasites are responsible for the devastating disease malaria that affects hundreds of millions of people each year. Blood stage parasites establish new permeability pathways (NPPs) in infected red blood cell membranes to facilitate the uptake of nutrients and removal of parasite waste products. Pharmacological inhibition of the NPPs is expected to lead to nutrient starvation and accumulation of toxic metabolites resulting in parasite death. Here, we have screened a curated library of antimalarial compounds, the MMV Malaria Box, identifying two compounds that inhibit NPP function. Unexpectedly, metabolic profiling suggested that both compounds also inhibit dihydroorotate dehydrogense (DHODH), which is required for pyrimidine synthesis and is a validated drug target in its own right. Expression of yeast DHODH, which bypasses the need for the parasite DHODH, increased parasite resistance to these compounds. These studies identify two potential candidates for therapeutic development that simultaneously target two essential pathways in Plasmodium, NPP and DHODH.

UR - http://www.scopus.com/inward/record.url?scp=84996587399&partnerID=8YFLogxK

U2 - 10.1038/srep37502

DO - 10.1038/srep37502

M3 - Article

AN - SCOPUS:84996587399

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 37502

ER -